Colin D. Marchant, MD
Associate Professor
Boston University School of Medicine
Dept of Pediatrics
Infectious Diseases Section

MD, McGill University



Active Staff Privileges
Boston Medical Center
Pediatrics
Infectious Diseases Section



A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a human monoclonal antibody, REGN2222, for the prevention of medically attended RSV infection in
12/23/2015 - 06/17/2017 (PI)
Regeneron Pharmaceuticals, Inc.

A Safety and Immunogenicity Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents
10/01/2003 - 12/31/2016 (PI)
Merck & Company, Inc.

A phase II, observer-blind, randomized, controlled, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals quadrivalent influenza vaccine candidate
10/23/2013 - 09/30/2016 (PI)
GlaxoSmithKline, Inc.

A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX New Seed Process (NSP) Administered Concomitantly with M-M-R II
08/04/2014 - 08/03/2016 (PI)
Merck, Sharp & Dohme Corp

A phase IIIb, open, randomized, controlled, multicenter study to assess the co-administration of Rotarix (GlaxoSmithKline Biologicals') with Hib-MenCY-TT
07/01/2013 - 06/30/2016 (PI)
GlaxoSmithKline, Inc.

A phase IIIA, randomized, observer-blind, controlled, multinational study to evaluate the safety and immunogenicity of GSK Biologicals' MMR vaccine (209762)
08/15/2014 - 07/31/2015 (PI)
GlaxoSmithKline, Inc.

A phase IIIA, blinded randomized controlled multinational consistency study to evaluate the immunogenicity and safety of GSK Biologicals' MMR Vaccine (209762) compared to Merck's
10/01/2012 - 06/30/2015 (PI)
GlaxoSmithKline, Inc.

Immunogenicity and Safety of GSK Biologicals' Combined Measles-Mumps-Rubella Vaccine in Subjects Four to Six Years of Age
07/01/2012 - 06/30/2015 (PI)
GlaxoSmithKline, Inc.

A Phase III Double blind, randomized, multicenter, controlled study to evaluate the safety, tolerability and immunogenicity of measles, mumps, rubella, varicella (MMRV) vaccine made with an alternativ
07/01/2012 - 06/30/2015 (PI)
Merck & Company, Inc.

A Phase 3, Open-label, Randomized, Parallel-group, Multi-center Study to Evaluate the Safety and Immunogenecity of Novartis Meningococcal ACWY Conugate Vaccine when Administered with Routine Infant Va
11/19/2008 - 11/18/2013 (PI)
Novartis Vaccines and Diagnostics, Inc.

Showing 10 of 45 results. Show All Results

Assessing Rates of Fever and Other Adverse Events in Children after US Influenza Vaccines Using Text
09/19/2014 - 09/18/2016 (PI)
CDC

Clinical Immunization Safety Assessment Safety (CISA) Center
09/29/2012 - 09/28/2013 (PI)
CDC

A double-blind, randomized controlled phase III study
01/12/2004 - 03/31/2013 (PI)
St. Louis University NIH

Vaccine Safety - CISA
09/01/2002 - 09/29/2012 (PI)
America's Health Insurance Plans CDC

Vaccine Safety - CISA: Phase I H1N1 funding
07/01/2010 - 06/30/2011 (PI)
America's Health Insurance Plans CDC

Clinical Immunization Safety A
09/30/2001 - 09/29/2004 (PI)
CDC



Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Loughlin AM, Hsu K, Silverio AL, Marchant CD, Pelton SI. Direct and indirect effects of PCV13 on nasopharyngeal carriage of PCV13 unique pneumococcal serotypes in Massachusetts'' children. Pediatr Infect Dis J. 2014 May; 33(5):504-10.View Related Profiles. PMID: 24670957; DOI: 10.1097/INF.0000000000000279;.
  2. Marshall GS, Blatter M, Marchant C, Aris E, Mesaros N, Miller JM. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY-TT) given at 12-15 months of age. Pediatr Infect Dis J. 2013 Jun; 32(6):662-8. PMID: 23340564; DOI: 10.1097/INF.0b013e3182840e35;.
  3. Williams SE, Edwards KM, Baxter RP, LaRussa PS, Halsey NA, Dekker CL, Vellozzi C, Marchant CD, Donofrio PD, Reimschisel TE, Berger M, Gidudu JF, Klein NP. Comprehensive assessment of serious adverse events following immunization by health care providers. J Pediatr. 2013 Jun; 162(6):1276-81, 1281.e1. PMID: 23452584; DOI: 10.1016/j.jpeds.2013.01.028;.
  4. Pahud BA, Williams SE, Dekker CL, Halsey N, Larussa P, Baxter RP, Klein NP, Marchant CD, Sparks RC, Jakob K, Aukes L, Swope S, Barnett E, Lewis P, Berger M, Dreskin SC, Donofrio PD, Sejvar JJ, Slade BA, Gidudu J, Vellozzi C, Edwards KM. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013 Feb; 32(2):163-8.View Related Profiles. PMID: 23334340; DOI: 10.1097/INF.0b013e318271b90a;.
  5. Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C, Edwards KM, Klein J, Klein NP, LaRussa P, Sparks R, Jakob K. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.View Related Profiles. PMID: 23063829; DOI: 10.1016/j.vaccine.2012.09.074;.
  6. Bryant K, McVernon J, Marchant C, Nolan T, Marshall G, Richmond P, Marshall H, Nissen M, Lambert S, Aris E, Mesaros N, Miller J. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Hum Vaccin Immunother. 2012 Aug; 8(8):1036-41. PMID: 22617844; PMCID: PMC3551873; DOI: 10.4161/hv.20357;.
  7. Rowhani-Rahbar A, Klein NP, Dekker CL, Edwards KM, Marchant CD, Vellozzi C, Fireman B, Sejvar JJ, Halsey NA, Baxter R. Biologically plausible and evidence-based risk intervals in immunization safety research. Vaccine. 2012 Dec 17; 31(1):271-7. PMID: 22835735; DOI: 10.1016/j.vaccine.2012.07.024;.
  8. Halsey NA, Edwards KM, Dekker CL, Klein NP, Baxter R, Larussa P, Marchant C, Slade B, Vellozzi C. Algorithm to assess causality after individual adverse events following immunizations. Vaccine. 2012 Aug 24; 30(39):5791-8. PMID: 22507656.
  9. Cherry JD, Tan T, Wirsing von König CH, Forsyth KD, Thisyakorn U, Greenberg D, Johnson D, Marchant C, Plotkin S. Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis. 2012 Jun; 54(12):1756-64. PMID: 22431797; PMCID: PMC3357482; DOI: 10.1093/cid/cis302;.
  10. Schumacher SK, Marchant CD, Loughlin AM, Bouchet V, Stevenson A, Pelton SI. Prevalence and genetic diversity of nontypeable haemophilus influenzae in the respiratory tract of infants and primary caregivers. Pediatr Infect Dis J. 2012 Feb; 31(2):145-9.View Related Profiles. PMID: 22051860; PMCID: PMC3261374; DOI: 10.1097/INF.0b013e31823aaeb3;.
Showing 10 of 71 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 71 publications over 28 distinct years, with a maximum of 7 publications in 2011

YearPublications
19801
19821
19832
19843
19852
19862
19873
19892
19902
19913
19922
19931
19942
19952
19992
20001
20012
20023
20042
20053
20066
20071
20083
20103
20117
20126
20133
20141
Contact for Mentoring:


670 Albany St Biosquare III
Boston MA 02118
Google Map


Marchant's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department